Retinoblastoma - Clinical Spectrum and Treatment Outcome in Children

Alia Ahmad 1, Fauzia Shafi Khan 2, Wasila Shamim 1, Asif Hanif 3, Carlos Rodriguez-Galindo 4
1. Department of Paediatric Haematology/Oncology, Children’s Hospital, Lahore; 2. Department of Paediatric Haematology & Transfusion Medicine, Children’s Hospital, Lahore; 3. Gulab Devi Hospital, Lahore; 4. Department of Global Pediatric Medicine St. Jude Children’s Research Hospital, Memphis TN, USA

Abstract

Background: To analyze outcome of retinoblastoma (RB) in resource limited settings

Methods: In this descriptive study, patients of retinoblastoma were treated according to UKCCSG RB 2005 11 protocol with main chemotherapy including Vincristine, Etoposide, Carboplatin and intrathecal Cytarabine called JOE protocol. These protocols were given 3 weeks apart in the chemotherapy bay on outpatient basis. Total 6 courses were given to these patients. The patients presenting with huge tumour with proptosis were offered two courses of chemotherapy (Neoadjuvant) before Enucleation (Removal of orbit and optic nerve) done as upfront Enucleation not possible without mutilating surgery-Exenteration. In our study Group A included patients who refused Enucleation and opted out of recommended treatment plan and Group B patients had Enucleations done and followed treatment plans

Results: Total 68 patients with age ranging from <1 to 7 years (95% <5 yrs) were included. Thirty seven percent presented with bilateral retinoblastoma, fifty six percent with optic nerve involvement and 18% with brain metastasis. 30/68(44%) defaulted treatment, and 33/68 (49%) refused enucleation at diagnosis. Only 3/68(5%) had bilateral enucleation and 50/68(73%) unilateral enucleation with laser therapy in 7/68(10%). Total 52% completed treatment, 26% left against medical advice and 9% expired due to metastatic and progressive disease and sepsis. 9/68 (13%) patients relapsed. Neoadjuvant chemotherapy was given in 59% with 61% of total abandonment and 50% of deaths in this group. The number of bilateral RB was increased to 37% as compared to 18%. Abandonment increased from 13% to 26%.

Conclusion: Mortality of 9% can be reduced by early diagnosis and early treatment. Management of RB needs efficient multidisciplinary team and long term sustainable programs to improve survival. The Neoadjuvant group needs extensive follow up and counselling to decrease abandonment.

Key Words: Retinoblastoma, neoadjuvant chemotherapy, UKCCSG RB 2005 11 protocol, Enucleation

Introduction

While Retinoblastoma is highly curable in developed countries, the outcome is still dismal in Pakistan. Retinoblastoma is the most common primary intraocular malignancy in pediatric population. When Retinoblastoma is diagnosed in early intraocular stages the probability of disease free survival in good centers have been 80-90% with Enucleation of the affected eye, a simple surgical procedure usually curative in intraocular retinoblastoma. RB is one of the more common malignancies in pediatric oncology in developing countries. The annual incidence of retinoblastoma in USA is 3.8 cases per million and higher in Africa up to 20 cases per million children under 5 with survival rates upto 30% and up to seven times that of Western Europe (4.1 per million) in Brazil and Mexico evidenced by population based studies and cancer registries data. In developed countries, sophisticated conservative strategies are used to preserve eyes with useful vision without changing the survival. Although these outcomes are very encouraging but the majority of the 8,000 children diagnosed with RB worldwide have not benefited from these trends. In developing countries the diagnosis is made quite late with extraocular metastasis therefore ocular and patient survival rates are much lower than in developed countries as it is difficult to treat even with most sophisticated and intense regimens. These cases depict longer lag times from the onset of symptoms to the final diagnosis made. Another critical factor greatly influencing the outcome is therapy refusal by parents against
recommended medical advice, however late diagnosis is given more attention than families opting out of treatment in literature. Therefore survival of these children in developing countries is affected by socioeconomic and cultural factors causing delays leading to extra-ocular dissemination than by the unavailability of advanced treatments as described for other childhood malignancies as ALL or other solid tumors.

In developing countries, multiple factors including late referrals due to lack of parental education and awareness among health professionals for early signs resulting in delayed diagnosis with extra-ocular presentation in 50 % of cases along with refusal of Enucleation and incomplete treatment. To improve survival and vision it is imperative to improve the referral systems with increased awareness of doctors and parents by community outreach program.

Patients and Methods
In this descriptive study, performed in department of Paediatric Haematology/Oncology of the Children’s Hospital & the Institute of Child Health Lahore from June 2013 to December 2015, patients of retinoblastoma were included. Patients were treated according to UKCCSG RB 2005 11 protocol with main chemotherapy including Vincristine, Etoposide, carboplatin and intrathecal Cytarabine called JOE protocol. Doses calculated according to body surface area. These protocols were given 3 weeks apart in the chemotherapy bay on outpatient basis. Total 6 courses were given to these patients. The patients presenting with huge tumor with proptosis were offered two courses of chemotherapy (Neoadjuvant) before Enucleation (Removal of orbit and optic nerve) done as upfront Enucleation not possible without mutilating surgery-Exenteration. In our study Group A includes patients who refused Enucleation and opted out of recommended treatment plan and Group B patients had Enucleations done and followed treatment plans.

Results
Total 68 patients with age ranging from< 1 to 7 years (95% <5 yrs) were included (Table 1). M: F Ratio was 1:1. These patients mainly presented with leukocoria of affected eye, squint and proptosis and huge disfiguring tumors or fungating masses along with loss of vision of the affected eye. (Figure 1 & 2). Thirty seven percent (25/68) presented with bilateral Retinoblastoma and 38/68 (56%) with optic nerve involvement (Figure B & D) and brain metastasis 12/68(18%). (Figure 3-6)30/68(44%) defaulter treatment (Table 2), and 33/68 (49%) refused Enucleation at diagnosis (Table 3). Only 3/68(5%) had bilateral Enucleation and 50/68(73%) unilateral Enucleation with laser therapy in 7/68(10%). Total 35/68 (52%) have completed treatment, 18/68 (26%) left against medical advice (LAMA) and 6/68 (9%) expired due to metastatic and progressive disease and sepsis. 9/68 (13%) patients relapsed (Table 4). Neoadjuvant chemotherapy was given in 40/68 (59%) with 61% of total abandonment and 50% of deaths in this group. When compared with the previous study presented in SIOP 2014 mortality decreased from 18 to 9% and defaulter trend decreased from 66% to 44% (30/68) and Neoadjuvant chemotherapy used in 59% cases as compared to 54%.The number of bilateral RB was increased to 25/68(37%) as compared to 10/56(18%).Abandonment increased from 13% to 26%.

Table1: Age distribution
<table>
<thead>
<tr>
<th>Age (years)</th>
<th>&lt; 1r</th>
<th>1-5</th>
<th>&gt;5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>20</td>
<td>44</td>
<td>4</td>
</tr>
<tr>
<td>%</td>
<td>30%</td>
<td>65%</td>
<td>5%</td>
</tr>
</tbody>
</table>

<5 Years=95%

Table2: Pattern of treatment course

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group A (Yes)</th>
<th>Group B (No)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Defaulter Treatment</td>
<td>30 (44%)</td>
<td>38 (56%)</td>
<td>0.000</td>
</tr>
</tbody>
</table>

p-value<0.05 is statistically significant

Table 3: Refusal of enucleation

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group A (Yes)</th>
<th>Group B (No)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refused Enucleation</td>
<td>33 (49%)</td>
<td>35 (51%)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

p-value<0.05 is statistically significant

Table4: Outcome of Retinoblastoma

<table>
<thead>
<tr>
<th></th>
<th>LAMA</th>
<th>Expired</th>
<th>Treatment Completed</th>
<th>Relapsed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>18</td>
<td>6</td>
<td>38</td>
<td>5</td>
</tr>
<tr>
<td>%</td>
<td>26</td>
<td>9</td>
<td>52</td>
<td>7</td>
</tr>
</tbody>
</table>

Figure 1: Extraocular Presentation

Figure 2: Leukocoria Right Eye
Discussion

In present study only 29% cases presented before one year of age and more than two thirds duration of symptoms longer than three months before diagnosis (lag period) significant predictors for presence of pathological high risk factors (HRF) indication need of adjuvant chemotherapy and radiotherapy. The mean age of diagnosis in Western children is reported as 18 months and median age at diagnosis in Indian children was 24 months. Delayed diagnosis is one of the two most important causes of advanced disease at presentation in developing countries as well as diagnosis at later ages as compared to the developed countries. The importance of lag time between presentation of symptoms and diagnosis with outcome modification was firstly emphasized by Brazilian researchers. This can be encouraged in LIC(Low Income Countries) where majority of patients present with advanced disease and high eventual mortality as in MIC/ developed countries survival increases up to 80% so they are focusing more on eye and vision preservation by doing screening of familial Retinoblastoma cases which is still as low as 23% in developing countries.

The second most important point in our study is behavior of families opting out of recommended treatment whether chemotherapy or Enucleation even if timely diagnosis is made in good centers. In our study 49% refused Enucleation at diagnosis and 44% defaulted chemotherapy with overall poor survival. 64% received chemotherapy at delayed schedules after Enucleations and 26% cases didn’t receive any treatment. As these patients were not treated in time with surgery, chemotherapy and radiotherapy they relapsed (13%) as compared to 3% in MIC and died (9%) due to progressive disease.

So in our study 52% cases able to complete therapy successfully and they are well but need further follow up and monitoring, the rest 48% eventually expired due to Retinoblastoma. Though estimated survival rate in LIC is 30% with 35% cases presenting in advanced stages and 40% refusing Enucleation and further management in Asia, Africa and Central America. In MIC(Middle Income Countries) Estimated survival is 60-75% cases with 10-15% cases presenting in advanced stages and only 30% estimated cases opting out of treatment while this trend is only 1% in HIC (High Income Countries with 95% estimated survival rate with 3% cases presenting in advanced stages at presentation).

In present study optic nerve involvement was present in 56% lower than in African Countries 68% to 78% but higher than in France 45% (1977-1990) but much lesser currently(3%) with increased risk of orbital and metastatic disease. In India there was 17% retrolaminar optic nerve involvement and 9% extrascleral and optic nerve transection invasion classified as microscopic residual disease and in 326 eyes over a period of 5 years and with median age of presentation 2 years requiring postoperative adjuvant chemotherapy and radiotherapy.

Neoadjuvant chemotherapy was given in 59% cases but data showed increased abandonment and deaths in this group though there are good results with up to 70% disease free survival with different chemotherapy regimens using etopside, ifosfamide and anthracyclines and up to 56% survival with less intensive chemotherapy in LIC like Mali. In advanced cases involving CNs and distant metastases routine chemotherapy and radiotherapy gives dismal results with eventual relapse and ultimately death in LIC and adequate palliation should be provided for these children but unfortunately is not adequately available in many centers.
While Eye conserving treatment in developed countries is the standard of care, we are struggling hard to save these children as they present very late and then they don’t adhere to the planned treatment. A more focus on how to improve acceptance of families for life saving procedure of enucleation and compliance of treatment and improved palliative and supportive care services as high intensity chemotherapy regimens are required to treat them and provision of adequate facilities for EBRT (external Beam Radiotherapy). As disease free survival in LIC is <50% with >30% presenting g with metastatic disease at diagnosis due to mainly sociocultural factors like treatment nonadherence and late diagnosis partly due to paucity of efficient multidisciplinary treatment centers it’s the need of time to establish awareness campaigns for early referrals. Early diagnosis campaigns, programs to prevent treatment nonadherence and twinning programs with high-income countries to increase survival like St. Jude Children Research Hospital USA. The need of multidisciplinary treatment centers in developing countries cannot be overemphasized for better management with significant roles of highly trained histopathologists, critical for identifying high risk patients as if missed and not given adjuvant chemotherapy might eventually progress and die of metastatic retinoblastoma. Trained radiologist, radiation oncologist and paediatric oncologist with improved supportive care services while giving intensive chemotherapy regimens and palliative care services are essential.

Conclusion
Mortality of 9% can be reduced by early diagnosis and early treatment. The Neoadjuvant group needs extensive follow up and counseling to decrease abandonment.

References
17. Antoneli CB, Ribeiro KB, Rodríguez-Galindo C. The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol 2011; 33: 29-70